Twist Bioscience Co. (NASDAQ:TWST) Shares Acquired by Charles Schwab Investment Management Inc.

Charles Schwab Investment Management Inc. increased its holdings in shares of Twist Bioscience Co. (NASDAQ:TWST) by 3.4% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 542,832 shares of the company’s stock after acquiring an additional 17,890 shares during the quarter. Charles Schwab Investment Management Inc. owned about 0.91% of Twist Bioscience worth $25,225,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently bought and sold shares of TWST. Thrivent Financial for Lutherans purchased a new stake in shares of Twist Bioscience in the 3rd quarter valued at approximately $43,992,000. State Street Corp grew its holdings in Twist Bioscience by 19.9% during the 3rd quarter. State Street Corp now owns 3,167,353 shares of the company’s stock worth $143,101,000 after acquiring an additional 526,028 shares in the last quarter. Wellington Management Group LLP grew its holdings in Twist Bioscience by 188.5% during the 3rd quarter. Wellington Management Group LLP now owns 797,737 shares of the company’s stock worth $36,042,000 after acquiring an additional 521,272 shares in the last quarter. Jennison Associates LLC boosted its holdings in shares of Twist Bioscience by 80.2% in the 4th quarter. Jennison Associates LLC now owns 680,778 shares of the company’s stock valued at $31,636,000 after buying an additional 302,884 shares in the last quarter. Finally, ARK Investment Management LLC boosted its holdings in shares of Twist Bioscience by 4.4% in the 4th quarter. ARK Investment Management LLC now owns 5,595,865 shares of the company’s stock valued at $260,040,000 after buying an additional 237,772 shares in the last quarter.

Insider Activity at Twist Bioscience

In other Twist Bioscience news, SVP Paula Green sold 1,259 shares of Twist Bioscience stock in a transaction dated Monday, February 3rd. The stock was sold at an average price of $49.35, for a total value of $62,131.65. Following the sale, the senior vice president now owns 132,014 shares of the company’s stock, valued at $6,514,890.90. This trade represents a 0.94 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director Robert Chess sold 5,000 shares of Twist Bioscience stock in a transaction dated Tuesday, January 7th. The shares were sold at an average price of $50.00, for a total value of $250,000.00. Following the completion of the sale, the director now directly owns 16,641 shares in the company, valued at approximately $832,050. This represents a 23.10 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 33,804 shares of company stock valued at $1,601,404 in the last three months. Corporate insiders own 3.01% of the company’s stock.

Twist Bioscience Stock Down 4.2 %

Shares of Twist Bioscience stock opened at $40.57 on Wednesday. The stock has a market capitalization of $2.42 billion, a P/E ratio of -12.00 and a beta of 2.15. The company has a quick ratio of 4.62, a current ratio of 4.96 and a debt-to-equity ratio of 0.03. The stock has a 50 day moving average price of $45.54 and a two-hundred day moving average price of $45.25. Twist Bioscience Co. has a 12-month low of $27.41 and a 12-month high of $60.90.

Twist Bioscience (NASDAQ:TWST) last posted its quarterly earnings results on Monday, February 3rd. The company reported ($0.53) EPS for the quarter, beating the consensus estimate of ($0.62) by $0.09. Twist Bioscience had a negative return on equity of 32.69% and a negative net margin of 59.76%. The firm had revenue of $88.70 million during the quarter, compared to analysts’ expectations of $86.96 million. During the same quarter in the prior year, the firm posted ($0.75) EPS. The company’s revenue for the quarter was up 24.1% on a year-over-year basis. Equities analysts expect that Twist Bioscience Co. will post -2.12 earnings per share for the current year.

Wall Street Analysts Forecast Growth

TWST has been the subject of a number of recent research reports. Robert W. Baird increased their price target on shares of Twist Bioscience from $48.00 to $54.00 and gave the stock an “outperform” rating in a research note on Tuesday, February 4th. Barclays set a $58.00 price target on shares of Twist Bioscience and gave the company an “overweight” rating in a report on Monday, February 3rd. Wolfe Research assumed coverage on shares of Twist Bioscience in a research note on Friday, December 13th. They issued an “outperform” rating and a $60.00 price objective on the stock. JPMorgan Chase & Co. raised their target price on shares of Twist Bioscience from $35.00 to $40.00 and gave the stock an “underweight” rating in a research report on Tuesday, February 4th. Finally, Scotiabank restated an “outperform” rating on shares of Twist Bioscience in a report on Tuesday, February 4th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and eight have issued a buy rating to the stock. According to MarketBeat.com, Twist Bioscience currently has a consensus rating of “Moderate Buy” and an average target price of $54.40.

Twist Bioscience Company Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.